Business / Licensing
The theranostics market is growing rapidly, creating demand for safe and scalable solutions to deliver next-generation radiopharmaceuticals. Our patented process provides a proven framework for radioactive drug handling, with applications across leading isotopes including zirconium-89 (Zr-89), lead-212 (Pb-212), lutetium-177 (Lu-177), and actinium-225 (Ac-225).
This innovation improves the safety and efficiency of radiopharmaceutical administration by incorporating shielded infusion methods that align with regulatory and clinical standards.
Ideal partners include pharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), device and shielding developers, radiopharmacies, and clinical networks expanding their theranostics programs. By licensing this process, companies can accelerate development, reduce regulatory risk, and strengthen their market position in nuclear medicine.
Technical / R&D
The process integrates seamlessly with automated infusion pumps, hot cells, and radiopharmacy equipment to improve radioactive drug handling, reduce occupational exposure, and ensure USP <825> compliance. By optimizing workflows at radiopharmacies, cyclotron facilities, and nuclear medicine clinics, this innovation supports reliable theranostics drug delivery while enhancing safety standards.
Engineers, R&D teams, and clinical operators developing radiopharmaceutical devices or workflows can license this patent to strengthen product design, safety, and regulatory readiness.